Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Utility of Liquid Biopsy in Brigatinib-Treated ALK+ NSCLC (CUBIK)
2024-511317-38-00Phase 2Completed
- Sponsor
- Fundación GECP
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brigatinib in ALK-positive non-small cell lung cancer, sponsored by Fundación GECP. Primary endpoint: Overall response rate. Started Mar 2024; status: completed.
02
Drugs
brigatinib
03
Conditions
ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on 2024-511317-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511317-38-00.